About Athenex
Athenex is a global biopharmaceutical company that has been dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 by Dr. Johnson Lau and Dr. Rudy Mazzocchi with a vision to create innovative cancer treatments that can improve patient outcomes.
The company's mission is to develop safe and effective therapies for patients suffering from various types of cancers. Athenex has a strong focus on research and development, which has led to the creation of several promising drug candidates that are currently in clinical trials.
One of Athenex's most promising drug candidates is Oraxol, an oral formulation of paclitaxel that has shown significant promise in treating breast cancer. Oraxol combines paclitaxel with an absorption enhancer called HM30181A, which allows for better absorption into the bloodstream and improved efficacy.
Another promising drug candidate from Athenex is KX2-391, a topical ointment being developed for the treatment of actinic keratosis (AK), a precancerous skin condition caused by sun damage. KX2-391 works by inhibiting Src kinase activity, which plays a key role in AK development.
In addition to its drug development efforts, Athenex also operates manufacturing facilities in both the US and China. These facilities allow Athenex to produce its own drugs as well as provide contract manufacturing services for other companies.
Athenex's commitment to innovation extends beyond just its drug development efforts. The company also utilizes cutting-edge technology such as artificial intelligence (AI) and machine learning (ML) to help identify new drug targets and improve clinical trial design.
Overall, Athenex is an exciting biopharmaceutical company with a strong focus on developing innovative cancer treatments that can make a real difference in patients' lives. With its robust pipeline of drug candidates and state-of-the-art manufacturing facilities, it's clear that this company will continue making waves in the world of oncology research for years to come.